Hemoglobinopathies Market Research Report 2020-2025: Projected to Discern Stable Expansion During

Global Hemoglobinopathies Market Research Report: Information by Type (Thalassemia (Alpha Thalassemia, Beta Thalassemia), Sickle Cell Disease and other Hb Variant Diseases), Treatment (Stem-cell Transplantation, Blood Transfusions, Analgesics, Antibiotics, ACE inhibitors, Hydroxyurea), End User (Hospitals & Clinics, Diagnostics Laboratories and others) – Global Forecast till 2025

Market Scenario

The global hemoglobinopathies market is expected to grow significantly over the forecast period. It is anticipated that the market held a valuation of USD 5,800 million in 2018 and is projected to register a CAGR of around10.2% over the forecast period.Hemoglobinopathies is a group of blood disorders such as sickle cell disease, thalassemia, and many others. It is considered the most common inherited disease across the globe. Also, nowadays, hemoglobinopathies have become much more common in central and northern Europe, including Germany, due to immigration.

Download Sample of This Strategic Report- https://www.kennethresearch.com/sample-request-10159232

The rising prevalence of hemoglobin disorders such as sickle cell anemia, thalassemia, Hb C, and Hb E is estimated to be the high impact rendering driver of the market. According to the WHO, hemoglobin disorders are endemic in over 60% of the 229 countries affecting over 70% of births. As per the report published by the Centers for Disease Control and Prevention (CDC) in 2015, the initial screening of newborns to identify sickle cell disease (SCD) along with other hemoglobin disorders such as, alpha (α) and beta (β) thalassemia have also gained significant attention in recent years due to the change in the US demographics.

Unhygienic and poor healthcare infrastructure are some of the factors attributing to increase in the base of the target population in low-income regions such as South-East Asia, Mediterranean basin, and African region which will drive the market growth over the forecast period. However, the lack of treatment and diagnosis awareness may hamper the growth of the hemoglobinopathies market during the forecast period.

Segmentation

The global hemoglobinopathies market is segmented based on type, treatment, end users, and region.The global market for hemoglobinopathies, by type, is segmented into thalassemia, sickle cell disease, and other Hb variants diseases. Thalassemia is further classified as alpha thalassemia and beta thalassemia. Based on treatment, the market is classified into stem-cell transplantation, blood transfusions, analgesics, antibiotics, ACE inhibitors, and hydroxyurea. The market by end user has been classified into hospitals and clinics, diagnostics laboratories, and others.

The sickle cell disease segment is expected to hold the largest market share of the hemoglobinopathies market owing to the presence of strong product pipelines such as Lent Globin and rising prevalence of sickle cell disease. Also, based on treatment, the blood transfusion segment holds the largest market share owing to significant success rate and increasing adoption of this treatment option.In the current scope of the study, the segments mentioned above are covered into four global regions, namely, the Americas, Europe, Asia-Pacific, and the Middle East and Africa.

Download Sample of This Strategic Report- https://www.kennethresearch.com/sample-request-10159232

The hemoglobinopathies market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.The European hemoglobinopathies market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The hemoglobinopathies market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The hemoglobinopathies market in the Middle East and Africa has been segmented into the Middle East and Africa.

Key Players

Sanofi

Sangamo Therapeutics, Inc.

Global Blood Therapeutics

Neusoft Medical Systems Co., Ltd

Bluebird Bio, Inc.

Emmaus Life Sciences Inc.

Prolong Pharmaceuticals

Celgene Corporation

Alnylam Pharmaceuticals

Gamida Cell

Acceleron Pharma

Mast Therapeutic

HemaQuest Pharmaceuticals

Invenux

Regional Market Summary

Global Hemoglobinopathies Market Share (%), by Region, 2017

The Americas dominated the global market for hemoglobinopathies owing to the rising geriatric population within the region. As per the data suggested by the American Society of Hematology approximately 70,000 to 100,000 Americans have sickle cell disease, the most common form of an inherited blood disorder.

As per the Centers for Disease Control and Prevention (CDC) in 2010, the US incidence estimate for sickle cell trait (based on information provided by 13 states) was 73.1 cases per 1,000 black newborns, 3.0 cases per 1,000 white newborns, and 2.2 cases per 1,000 Asian or Pacific Islander newborns. The incidence estimates for Hispanic ethnicity (within 13 states) was 6.9 cases per 1,000 Hispanic newborns.

Request For Full Report- https://www.kennethresearch.com/sample-request-10159232

The rising participation of market players is also strongly impacting the growth of the Americas hemoglobinopathies market. For instance, in 2018, in Europe, Sanofi launched the first approved treatment for acquired thrombotic thrombocytopenic purpura (aTTP), bringing a new treatment option to patients who previously had none. In the US, this treatment was approved by the FDA in February 2019.

According to the Centers for Disease Control and Prevention (CDC), SCD affects approximately 100,000 Americans, which occurs among about one out of every 365 black or African American births.

Asia-Pacific (APAC) is expected to represent a phenomenal market growth throughout the forecast period due to the rising prevalence of hemoglobin disorders such as sickle cell anemia, thalassemia, Hb C, and Hb E.

On the other hand, the Middle East and Africa held the least share in the global hemoglobinopathies market due to the low economic development, especially within the African region.

Market Segmentation

Global Hemoglobinopathies Market, by Type

Thalassemia

Alpha Thalassemia

Beta Thalassemia

Sickle Cell Disease

Other Hb Variants Diseases

Global Hemoglobinopathies Market, by Treatment

Stem-Cell Transplantation

Blood Transfusions

Analgesics

Antibiotics

Ace Inhibitors

Hydroxyurea

Global Hemoglobinopathies Market, by End User      

Hospitals & Clinics

Diagnostics Laboratories

Others

Global Hemoglobinopathies Market, by Region

Americas

North America

US

Canada

Latin America

Europe

Western Europe

Germany

France

Italy

Spain

UK

Rest of Western Europe

Eastern Europe

Asia-Pacific

Japan

China

India

Australia

South Korea

Rest of Asia-Pacific

Middle East & Africa

Middle East

Africa

Intended Audience

Pharmaceutical companies

Government and private laboratories

Research and development (R&D) companies

Research laboratories

Market research and consulting service providers

About Kenneth Research:

Kenneth Research provides market research reports to different individuals, industries, associations and organizations with an aim of helping them to take prominent decisions. Our research library comprises of more than 10,000 research reports provided by more than 15 market research publishers across different industries. Our collection of market research solutions covers both macro level as well as micro level categories with relevant and suitable market research titles. As a global market research reselling firm, Kenneth Research provides significant analysis on various markets with pure business intelligence and consulting services on different industries across the globe. In addition to that, our internal research team always keep a track on the international and domestic market for any economic changes impacting the products’ demand, growth and opportunities for new and existing players.

Contact Us

Kenneth Research
Email: Sales@kennethresearch.com
Phone: +1 313 462 0609

James Bullock is a Research Expert with a demonstrated history of working in the professional training & coaching industry. Strong professional skilled in business strategy , Strategic Planning, Research Strategy, and Marketing. also have interest in new innovations and technology

Leave a Reply